Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 14, 2020

Bial reports additional data from Ongentys in Parkinson’s patients

Bial has reported new efficacy and tolerability data from Ongentys (opicapone), a catechol-O-methyltransferase (COMT) inhibitor, in Phase III studies involving patients with Parkinson's disease (PD) and Movement Disorders (MDS).

Bial has reported new efficacy and tolerability data from Ongentys (opicapone), a catechol-O-methyltransferase (COMT) inhibitor, in Phase III studies involving patients with Parkinson’s disease (PD) and Movement Disorders (MDS).

The data is being presented at the MDS 2020 Virtual Congress from 12-16 September.

According to a new post-hoc analysis of the real-world OPTIPARK study, the majority of treatment-emergent adverse events (TEAEs) that are at least possibly related to opicapone occurred within the first week of treatment.

The data further revealed a consistently low incidence of TEAEs from the third week onwards for six months.

Bial added that dyskinesia was the most frequently reported TEAE during the first week of treatment but did not significantly impact patient discontinuation.

The company also analysed three additional datasets from the BIPARK-I and II trials of the drug as a first-line adjunctive therapy to levodopa in PD patients with motor fluctuations.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

When compared to placebo and entacapone, opicapone was found to have shown added benefit in levodopa-treated PD patients recently diagnosed with motor fluctuations.

The drug also demonstrated an ability to decrease OFF-time as a first add-on to levodopa or in combination with levodopa regimens consisting of other anti-PD medications.

A home-diary data review involving 235 patients on 50mg of opicapone or entacapone in the BIPARK-I7 trial revealed that opicapone showed a greater increase in the proportion of patients who woke up in ON-status compared to entacapone.

The reduction in morning OFF-time was two times greater with opicapone than entacapone.

Bial Research & Development director Soares da Silva said: “Motor fluctuations can have a considerable impact on quality of life for people with Parkinson’s and our focus is on offering effective solutions with manageable tolerability.

“These new data demonstrate the potential for opicapone for use in a range of patients experiencing motor fluctuations, regardless of the point at which they occur.”

BIAL partnered with Neurocrine Biosciences in February 2017 to develop and commercialise opicapone in the US and Canada. Ongentys will be made available in the US this month.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy